Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ: TVTX )

19.52 +0.39 (+2.06%)
Streaming Delayed Price Updated: 1:56 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
4 Analysts Have This to Say About Travere Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
Via Benzinga
Where Travere Therapeutics Stands With Analysts
Via Benzinga
Recap: Travere Therapeutics Q3 Earnings
Travere Therapeutics (NASDAQ:TVTX) reported its Q3 earnings results on Thursday, October 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA
Via Benzinga
Expert Ratings for Travere Therapeutics
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings: 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's trading, 160 companies set new 52-week lows. 
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
From Travere Therapeutics, Inc.
Via GlobeNewswire
FDA Requests For Additional Monitoring For Travere Therapeutics' Sparsentan In Rare Kidney Disease
Via Benzinga
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Travere Therapeutics (NASDAQ:TVTX) reported Q3 sales of $53.50 million. Earnings fell to a loss of $69.66 million, resulting in a 3.91% decrease from last quarter. 
Via Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
Travere Therapeutics Reports Third Quarter 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Return On Capital Employed Overview
  
Via Benzinga
Recap: Travere Therapeutics Q2 Earnings
  Travere Therapeutics (NASDAQ:TVTX) reported its Q2 earnings results on Thursday, August 4, 2022. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
Data support the Company’s lead investigational product candidate sparsentan 
From Travere Therapeutics, Inc.
Via GlobeNewswire
Earnings Outlook For Travere Therapeutics
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Travere Therapeutics to Report Third Quarter 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
121 Stocks That Hit Their 52-Week Low
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks. 
Via InvestorPlace
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Says Travere's Sparsentan Data Not Sufficient For Accelerated Approval In One Indication
Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
4 Analysts Have This to Say About Travere Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.